Elvira López-‐OlivaMuñoz, EmiliaMuñozMartínez
48
199.
Musso, G., Gambino, R., Cassader, M., 2013. Cholesterol metabolism and the
pathogenesisof non-‐alcoholic steatohepatitis. ProgLipidRes52, 175-‐191.
200.
Caballero, F., Fernández, A., De Lacy, A.M. y col. 2009. Enhanced free cholesterol,
SREBP-‐2andStARexpression inhumanNASH. JHepatol 50, 789-‐796.
201.
Steffensen, K.R., Jakobsson, T., Gustafsson, J., 2013. Targeting liver X receptors in
inflammation. ExpertOpinTherTargets17, 977-‐990.
202.
Griffett, K., Solt, L.A., El-‐Gendy, B.l.-‐D. y col. 2013. A liver-‐selective LXR inverse
agonist that suppresseshepatic steatosis. ACSChemBiol 8, 559-‐567.
203.
Zhai, Y., Wada, T., Zhang, B., Khadem, S., Ren, S., Kuruba, R., Li, S., Xie, W., 2010. A
functional cross-‐talk between liver X receptor-‐α and constitutive androstane receptor
links lipogenesis andxenobiotic responses.Mol Pharmacol 78, 666-‐674.
204.
Roth, A., Looser, R., Kaufmann, M. y col. 2008. Regulatory cross-‐talkbetweendrug
metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X
receptor increase Insig-‐1expression.Mol Pharmacol 73, 1282-‐1289.
205.
Eissing, L., Scherer, T., Tödter, Ky col. 2013. Denovo lipogenesis inhuman fat and
liver is linked toChREBP-‐ßandmetabolichealth. Nat Commun4, 1528-‐1549.
